sprite-preloader
Anzeige
Mehr »
Samstag, 16.02.2019 Börsentäglich über 12.000 News von 595 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A0BLFX ISIN: SE0001137985 Ticker-Symbol: BTPC 
Aktie:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTIVE BIOTECH AB Chart 1 Jahr
1-Woche-Intraday-Chart
ACTIVE BIOTECH AB 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
0,329
0,392
10:03
09.08.2018 | 08:41
(6 Leser)
Schrift ändern:
(0 Bewertungen)

GlobeNewswire (Europe)·Mehr Nachrichten von GlobeNewswire (Europe)

Second quarter in brief

  • The company's partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago
  • The rights issue in April brought the company SEK 47.1 M

Events after the end of the period

  • The company announced that the Phase II LEGATO-HD trial evaluating efficacy and safety of laquinimod in Huntington's disease (HD) did not meet its primary endpoint to slow the progression of the disease. However, the secondary endpoint, reduction of brain atrophy, was met. Laquinimod showed excellent safety in the study
  • The company is initiating a scientific collaboration with the Wistar Institute in Philadelphia, PA, around tasquinimod to support future clinical development in multiple myeloma


Financial summary

SEK MApr-JunJan-JunFull year
2018 2017 2018 2017 2017
Net sales 5.7 5.1 10.5 9.8 20.2
Operating loss -7.3 -23.1 -15.9 -37.7 -102.5
Loss after tax -9.1 -24.4 -19.3 -40.2 -108.8
Earnings per share (SEK) -0.07 -0.20 -0.15 -0.33 -0.89
Cash and cash equivalents (at close of period) 45.6 47.7 25.2

For further information, please contact:

Helén Tuvesson, CEO
Tel: +46 (0)46 19 21 56



Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00

The report is also available at www.activebiotech.com (http://www.activebiotech.com).

Active Biotech AB - Interim Report January - June 2018 (http://hugin.info/1002/R/2209956/860170.pdf)



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire


© 2018 GlobeNewswire (Europe)